Sabby Management’s ImmunoCellular Therapeutics Ltd. IMUC.WS Stock Holding History

Sabby Management’s Portfolio IMUC.WS Stock Details IMUC.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-74,443	Closed	-$1K	–	158
2018 Q2	$1K	Buy	+74,443	New	+$1.72K	﹤0.01%	137
2018 Q1	–	Sell	-392,702	Closed	-$11.9K	–	226
2017 Q4	$16K	Sell	392,702 -27,401	-7%	-$1.24K	﹤0.01%	155
2017 Q3	$8K	Buy	420,103 +5,000	+1%	+$240	﹤0.01%	163
2017 Q2	$8K	Sell	415,103 -3,664	-0.9%	-$639	﹤0.01%	215
2017 Q1	$113K	Buy	418,767 +35,296	+9%	+$18.5K	0.01%	236
2016 Q4	$192K	Buy	+383,471	New	+$130K	0.01%	245

Other funds holding IMUC.WS

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's IMUC.WS Position: Q3 2018 in Review

Sabby Management sold out of ImmunoCellular Therapeutics Ltd. (IMUC.WS) in Q3 2018, closing a stake of 74,443 shares — an estimated $1K sold.

Sabby Management first reported a position in IMUC.WS in Q4 2016 and held it in 6 quarters. The position peaked at $192K in Q4 2016. 2 funds tracked by Wall St. Rank hold IMUC.WS as of Q3 2018.

Sabby Management reported no remaining ImmunoCellular Therapeutics Ltd. position as of Q3 2018 after selling out during the quarter.
Sabby Management sold 74,443 ImmunoCellular Therapeutics Ltd. shares in Q3 2018, an estimated $1K.
Sabby Management first reported a position in ImmunoCellular Therapeutics Ltd. in Q4 2016 and held it in 6 quarters.
Sabby Management's ImmunoCellular Therapeutics Ltd. position peaked at $192K in Q4 2016.
2 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics Ltd. as of Q3 2018.

Based on Sabby Management's 13F filing for Q3 2018, filed 14 Nov 2018.